Table 2.

Adverse events up to Day 28

	Phase Ia				Phase Ib		Total, n
	Cohort I (n = 3)	Cohort II (n = 3)	Cohort III (n = 6)	Cohort IV (n = 3)	Cohort A (n = 3)	Cohort B (n = 6)
Adverse event	0	1	2	1	3	3	10
Relationship to MSCs treatment
Definitely related	0	0	0	0	0	0	0
Probably related	0	0	0	0	0	0	0
Possibly related	0	0	1	0	1	2	4
Unlikely to be related	0	1	1	1	2	1	6
Not related	0	0	0	0	0	0	0
Severity level
Level 1	0	0	1	1	0	2	4
Level 2	0	1	1	0	2	1	5
Level 3	0	0	0	0	1	0	1
Level 4	0	0	0	0	0	0	0
Level 5	0	0	0	0	0	0	0
Serious adverse event	0	0	0	0	0	0	0
Adverse events resulted in death	0	0	0	0	0	0	0
Categories
Rash	0	1	1	0	0	0	2
Fever	0	0	0	0	0	2	2
Upper respiratory tract infection	0	0	0	0	1	0	1
Influenza-like symptoms	0	0	0	1	0	0	1
Kidney calculi	0	0	1	0	0	0	1
Diarrhea	0	0	0	0	1	0	1
Hemorrhoids	0	0	0	0	0	1	1
Bleeding gums	0	0	0	0	1	0	1
Adverse events outcome
Recovered	0	0	0	1	3	0	4
Improvement	0	1	2	0	0	3	6
Persistence	0	0	0	0	0	0	0
Aggravation	0	0	0	0	0	0	0
Sequelae	0	0	0	0	0	0	0
Death	0	0	0	0	0	0	0